Novus Therapeutics with ticker code (NVUS) now have 3 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 43 and 27 calculating the mean target price we have 35. Given that the stocks previous close was at 17 this is indicating there is a potential upside of 105.9%. The day 50 moving average is 20.7 while the 200 day moving average is 13.83. The market capitalisation for the company is $24m. Find out more information at: http://novustherapeutics.com
Novus Therapeutics, a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics is headquartered in Irvine, California.